UK markets closed
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • FTSE 250

    23,608.79
    -221.39 (-0.93%)
     
  • AIM

    1,266.98
    -5.42 (-0.43%)
     
  • GBP/EUR

    1.1661
    -0.0022 (-0.19%)
     
  • GBP/USD

    1.3681
    -0.0040 (-0.29%)
     
  • BTC-GBP

    31,423.46
    -1,341.43 (-4.09%)
     
  • CMC Crypto 200

    1,067.20
    -35.86 (-3.25%)
     
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • DOW

    34,798.00
    +33.18 (+0.10%)
     
  • CRUDE OIL

    73.95
    +0.65 (+0.89%)
     
  • GOLD FUTURES

    1,750.60
    +0.80 (+0.05%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • HANG SENG

    24,192.16
    -318.82 (-1.30%)
     
  • DAX

    15,531.75
    -112.22 (-0.72%)
     
  • CAC 40

    6,638.46
    -63.52 (-0.95%)
     

Insights on the Hematopoietic Stem Cell Transplantation Global Market to 2027 - Key Drivers, Restraints and Opportunities

·7-min read

Dublin, Aug. 03, 2021 (GLOBE NEWSWIRE) -- The "Hematopoietic Stem Cell Transplantation (HSCT) Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow, or umbilical cord blood are transplanted into the patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources; 1) autologous, that uses stem cells from the patient's own body, 2) and allogeneic that sources stem cells from a donor's body. According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years.

Market Dynamics

The global hematopoietic stem cell transplantation market is expected to witness significant growth during the forecast period owing to the increasing prevalence of leukemia and lymphoma. According to Center for Disease Control and Prevention (CDC), in the U.S., around 45,360 people were diagnosed with leukemia in 2013, leading to 23,549 fatalities (13,625 men and 9,924 women). According to the same source the condition is more prevalent among men than women. Leukemia accounts for around 3% of all new cancer cases.

Key features of the study:

  • This report provides in-depth analysis of the global hematopoietic stem cell transplantation market, market size (US$ Mn), and compound annual growth rate (CAGR %) for the forecast period 2020-2027, considering 2019 as the base year

  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players

  • It profiles key players in the global hematopoietic stem cell transplantation market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

  • Key players covered as a part of this study are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.

  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics

  • The global hematopoietic stem cell transplantation market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the hematopoietic stem cell transplantation market, research and consulting firms, new entrants, and financial analysts.

Key Topics Covered:

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics

  • Drivers

  • Restraints

  • Market Opportunities

  • Impact Analysis

  • Key Developments

  • Pipeline Analysis

  • PEST Analysis

  • Reimbursement Scenario

  • Regulatory Scenario

  • Epidemiology

  • Government Initiatives

  • Treatment Algorithm

4. Impact Analysis of COVID-19

  • COVID-19 Epidemiology

  • Guidelines for COVID-19 Management in Hematopoietic Stem Cell Transplantation (HSCT)

  • Impact of COVID-19 on Clinical Trials

5. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, 2016 - 2027, (US$ Million)

  • Introduction

  • Market Share Analysis, 2020 and 2027 (%)

  • Y-o-Y Growth Analysis, 2017 - 2027

  • Segment Trends

  • Autologous

  • Introduction

  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

  • Allogeneic

  • Introduction

  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication, 2016 - 2027, (US$ Million)

  • Introduction

  • Market Share Analysis, 2020 and 2027 (%)

  • Y-o-Y Growth Analysis, 2017 - 2027

  • Segment Trends

  • Acute Myeloid Leukemia (AML)

  • Introduction

  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

  • Acute Lymphoblastic Leukemia (ALL)

  • Introduction

  • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

  • Hodgkin lymphoma (HL)

  • Introduction

  • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

  • Non-Hodgkin Lymphoma (NHL)

  • Introduction

  • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

  • Multiple Myeloma (MM)

  • Introduction

  • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

  • Other Non-malignant Disorders

  • Introduction

  • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application, 2016 - 2027, (US$ Million)

  • Introduction

  • Market Share Analysis, 2020 and 2027 (%)

  • Y-o-Y Growth Analysis, 2017 - 2027

  • Segment Trends

  • Bone Marrow Transplant (BMT)

  • Introduction

  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

  • Peripheral Blood Stem Cells Transplant (PBSCT)

  • Introduction

  • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

  • Cord Blood Transplant (CBT)

  • Introduction

  • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction

  • Market Share Analysis, By Region, 2020 and 2027 (%)

  • Y-o-Y Growth Analysis, By Region, 2017 - 2027

  • Regional Trends

  • North America

  • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)

  • U.S.

  • Canada

  • Europe

  • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)

  • U.K.

  • Germany

  • Italy

  • France

  • Spain

  • Russia

  • Rest of Europe

  • Latin America

  • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)

  • Brazil

  • Mexico

  • Argentina

  • Rest of Latin America

  • Asia Pacific

  • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)

  • China

  • Japan

  • India

  • ASEAN

  • Australia

  • South Korea

  • Rest of Asia Pacific

  • Middle East

  • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)

  • GCC

  • Israel

  • Rest of Middle East

  • Africa

  • Market Size and Forecast, By Transplant Type, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Application, 2016 - 2027, (US$ Million)

  • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)

  • North Africa

  • Central Africa

  • South Africa

9. Competitive Landscape

  • Company Profiles

  • Pluristem Therapeutics Inc.

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • CellGenix GmbH

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • Regen Biopharma Inc.

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • Lonza Group

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • Kiadis Pharma

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • Taiga Biotechnologies, Inc.

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • Takeda Pharmaceutical Company Limited

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • Escape Therapeutics, Inc.

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • Bluebird Bio

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • Talaris Therapeutics, Inc.

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • Marker Therapeutics Inc.

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

  • Stempeutics Research Pvt Ltd.

  • Company Overview

  • Product Portfolio

  • Financial Performance

  • Recent Highlights

  • Strategies

10. Section

  • References

  • Research Methodology

  • About us and Sales Contact

For more information about this report visit https://www.researchandmarkets.com/r/4gdz2z

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting